Sangamo Biosciences (SGMO) Releases Earnings Results, Beats Expectations By $0.02 EPS

Sangamo Biosciences (SGMO) reported quarterly earnings results on Monday, May-2-2016. The company said it had a profit of $-0.23 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.02. Analysts had a consensus of $-0.25. The company posted revenue of $3.94 million in the period, compared to analysts expectations of $5.49 million. The company’s revenue was down -70.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.08 EPS.

Sangamo Biosciences closed down -0.24 points or -3.62% at $6.39 with 8,08,739 shares getting traded on Wednesday. Post opening the session at $6.59, the shares hit an intraday low of $6.25 and an intraday high of $6.5936 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Jul 17, 2015, Edward O Ii Lanphier (President & CEO) sold 25,000 shares at $10.43 per share price. According to the SEC, on Jul 14, 2015, Henry Ward Wolff (Exec VP & CFO) sold 12,000 shares at $10.00 per share price. On Jun 9, 2015, Dale G Ando (VP, Therapeutic Dev. & CMO) sold 15,000 shares at $12.29 per share price, according to the Form-4 filing with the securities and exchange commission.

Sangamo Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research development and commercialization of engineered DNA-binding proteins as therapeutic products. The main focus for the Company is the development of novel human therapeutics and it is building a pipeline of ZFP Therapeutics. The Company’s lead ZFP Therapeutic SB-728-T a ZFN-modified autologous T-cell product is under development for the treatment of HIV/AIDS. The Company’s clinical stage programs also include SB-728-HSPC for the treatment of HIV/AIDS SB-BCLmR-HSPC to treat Beta-thalassemia major and CERE-110 for the treatment of Alzheimer’s disease. Its pre-clinical products include SB-913 for the treatment of Hunter Syndrome and SB-318 for the treatment of Hurler Syndrome.

Sangamo Biosciences

Leave a Reply

Sangamo Biosciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Sangamo Biosciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.